Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Efavirenz

FDA-approved product (capsule, oral), marketed as Efavirenz, Sustiva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Efavirenz
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Efavirenz in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Efavirenz with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection

    NCT04296695 · start 2021-07-14

    Registered record
    Registry ID
    NCT04296695
    Conditions
    HIV-1-infection
    Interventions
    B/F/TAF; TDF/3TC/EFV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-07-14
    Completion
    2025-06-06
    Enrolment
    202

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionB/F/TAF; TDF/3TC/EFV
    PhasePhase 4
    Registry statusCompleted

  • Metformin's Effect on Drug Metabolism in Patients With Type 2 Diabetes

    NCT04504045 · start 2020-09-01

    Registered record
    Registry ID
    NCT04504045
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Metformin; Caffeine; Efavirenz; Losartan; Omeprazol; Metoprolol; Midazolam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2020-09-01
    Completion
    2022-05-10
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionMetformin; Caffeine; Efavirenz; Losartan +3 more
    PhasePhase 1
    Registry statusTerminated

  • A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants

    NCT04459598 · start 2020-08-19

    Registered record
    Registry ID
    NCT04459598
    Conditions
    Healthy Subjects; Drug-drug Interaction; Pharmacokinetics; Quizartinib
    Interventions
    Efavirenz; Quizartinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-08-19
    Completion
    2020-10-14
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects; Drug-drug Interaction; Pharmacokinetics; Quizartinib
    InterventionEfavirenz; Quizartinib
    PhasePhase 1
    Registry statusCompleted

  • Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

    NCT03983239 · start 2019-06-21

    Registered record
    Registry ID
    NCT03983239
    Conditions
    Healthy Volunteers
    Interventions
    Fedratinib; Rifampin; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-21
    Completion
    2019-11-06
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionFedratinib; Rifampin; Efavirenz
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy

    NCT03982277 · start 2019-04-30

    Registered record
    Registry ID
    NCT03982277
    Conditions
    Tuberculosis
    Interventions
    Rifampin 300 Mg Oral Capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-04-30
    Completion
    2021-07-23
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis
    InterventionRifampin 300 Mg Oral Capsule
    PhasePhase 2
    Registry statusCompleted

  • Optimization of Antiretroviral Therapy

    NCT02935075 · start 2018-03-05

    Registered record
    Registry ID
    NCT02935075
    Conditions
    HIV Infections
    Interventions
    Tenofovir disoproxil fumarate; Lamivudine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-03-05
    Completion
    2019-08-31
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTenofovir disoproxil fumarate; Lamivudine; Efavirenz
    PhasePhase 4
    Registry statusCompleted

  • Extended Duration Artemether-lumefantrine Treatment for Malaria in Children

    NCT03453840 · start 2018-02-21

    Registered record
    Registry ID
    NCT03453840
    Conditions
    Uncomplicated Plasmodium Falciparum Malaria
    Interventions
    Artemether-lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-02-21
    Completion
    2021-08-31
    Enrolment
    305

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUncomplicated Plasmodium Falciparum Malaria
    InterventionArtemether-lumefantrine
    PhasePhase 4
    Registry statusCompleted

  • Gut Microbiota and Immune Recovery

    NCT03478540 · start 2017-12-01

    Registered record
    Registry ID
    NCT03478540
    Conditions
    HIV-1-infection
    Interventions
    Anti-Retroviral Agents
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-12-01
    Completion
    2019-05-30
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionAnti-Retroviral Agents
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

    NCT02777229 · start 2016-07

    Registered record
    Registry ID
    NCT02777229
    Conditions
    HIV-1 Infection
    Interventions
    Dolutegravir 50 mg; Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg; Efavirenz 400 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-07
    Completion
    2021-07
    Enrolment
    616

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDolutegravir 50 mg; Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg; Efavirenz 400 mg
    PhasePhase 3
    Registry statusCompleted

  • Interaction With HIV Antiretroviral Agents

    NCT02556268 · start 2016-02-23

    Registered record
    Registry ID
    NCT02556268
    Conditions
    HIV-DDI
    Interventions
    Riociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD; TRIUMEQ; Antiretroviral protease inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-23
    Completion
    2016-12-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-DDI
    InterventionRiociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD +2 more
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

    NCT01789879 · start 2014-03-04

    Registered record
    Registry ID
    NCT01789879
    Conditions
    HIV; Contraception
    Interventions
    Levonorgestrel; Nevirapine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-04
    Completion
    2015-03-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Contraception
    InterventionLevonorgestrel; Nevirapine; Efavirenz
    PhasePhase 2
    Registry statusCompleted

  • Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection

    NCT01900015 · start 2014-02-03

    Registered record
    Registry ID
    NCT01900015
    Conditions
    HCV Coinfection; HIV Infection
    Interventions
    Raltegravir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-02-03
    Completion
    2017-01-17
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Coinfection; HIV Infection
    InterventionRaltegravir; Efavirenz
    PhasePhase 4
    Registry statusCompleted

  • EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

    NCT01886404 · start 2013-12-01

    Registered record
    Registry ID
    NCT01886404
    Conditions
    HIV Infection
    Interventions
    Efavirenz
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-12-01
    Completion
    2014-08-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionEfavirenz
    PhaseNot recorded
    Registry statusCompleted